A pharmacogenomic approach validates AG-221 as an effective and on-target therapy in IDH2 mutant AML

被引：0
|
作者：
L M Kats
S J Vervoort
R Cole
A J Rogers
G P Gregory
E Vidacs
J Li
R Nagaraja
K E Yen
R W Johnstone
机构：
[1] Cancer Therapeutics Program,The Sir Peter MacCallum Department of Oncology
[2] Peter MacCallum Cancer Centre,undefined
[3] University of Melbourne,undefined
[4] Monash Haematology,undefined
[5] Monash Health and School of Clinical Sciences at Monash Health,undefined
[6] Monash University,undefined
[7] Bioinformatics Core,undefined
[8] Peter MacCallum Cancer Centre,undefined
[9] Agios Pharmaceuticals,undefined
来源：
Leukemia | 2017年 / 31卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1466 / 1470
页数：4
相关论文
共 28 条
  • [1] A pharmacogenomic approach validates AG-221 as an effective and on-target therapy in IDH2 mutant AML
    Kats, L. M.
    Vervoort, S. J.
    Cole, R.
    Rogers, A. J.
    Gregory, G. P.
    Vidacs, E.
    Li, J.
    Nagaraja, R.
    Yen, K. E.
    Johnstone, R. W.
    LEUKEMIA, 2017, 31 (06) : 1466 - 1470
  • [2] Optimizing Next-Generation AML Therapy: Activity of Mutant IDH2 Inhibitor AG-221 in Preclinical Models
    Thomas, Daniel
    Majeti, Ravindra
    CANCER DISCOVERY, 2017, 7 (05) : 459 - 461
  • [3] AG-221 offers a survival advantage in a primary human IDH2 mutant AML xenograft model
    Ellwood-Yen, Kate
    Wang, Fang
    Travins, Jeremy
    Chen, Yue
    Yang, Hua
    Straley, Kim
    Choe, Sung
    Dorsch, Marion
    Agresta, Sam
    Schenkein, David
    Biller, Scott
    Su, Michael
    CANCER RESEARCH, 2014, 74 (19)
  • [4] AG-221 Offers a Survival Advantage In a Primary Human IDH2 Mutant AML Xenograft Model
    Yen, Katharine
    Wang, Fang
    Travins, Jeremy
    Chen, Yue
    Yang, Hua
    Straley, Kim
    Choe, Sung
    Dorsch, Marion
    Schenkein, David P.
    Agresta, Samuel
    Biller, Scott
    Su, Michael
    BLOOD, 2013, 122 (21)
  • [5] Hitting the target in IDH2 mutant AML
    Wouters, Bas J.
    BLOOD, 2017, 130 (06) : 693 - 694
  • [6] AG-221, first-in-class IDH2 mutation inhibitor shows promise
    Nature Reviews Clinical Oncology, 2014, 11 (6) : 302 - 302
  • [7] AG-221, a Small Molecule Mutant IDH2 Inhibitor, Remodels the Epigenetic State of IDH2-Mutant Cells and Induces Alterations in Self-Renewal/Differentiation in IDH2-Mutant AML Model in Vivo
    Shih, Alan H.
    Shank, Kaitlyn R.
    Meydan, Cem
    Intlekofer, Andrew M.
    Ward, Patrick
    Thompson, Craig B.
    Melnick, Ari M.
    Travins, Jeremy
    Straley, Kim
    Gliser, Camelia
    Yen, Katherine
    Levine, Ross L.
    BLOOD, 2014, 124 (21)
  • [8] Discovery of AG-221: A first-in-class inhibitor of IDH2 mutant enzymes for the treatment of acute myelogenous leukemia
    Travins, Jeremy
    Saunders, Jeffrey
    Salituro, Francesco
    Popovici-Muller, Janeta
    Yen, Katharine
    Straley, Kimberly
    Hansen, Erica
    Wang, Fang
    Gross, Stefan
    Dang, Lenny
    Yang, Hua
    Utley, Luke
    Chen, Yue
    Silverman, Lee
    Agresta, Sam
    Su, Michael
    Biller, Scott
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 250
  • [9] ENASIDENIB (AG-221), A SELECTIVE ORAL INHIBITOR OF MUTANT ISOCITRATE DEHYDROGENASE 2 (IDH2) ENZYME, IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS)
    Stein, E. M.
    Fathi, A. T.
    DiNardo, C. D.
    Pollyea, D. A.
    Swords, R. T.
    Roboz, G. J.
    Collins, R.
    Sekeres, M. A.
    Stone, R. M.
    Attar, E. C.
    Tosolini, A.
    Xu, Q.
    Amatangelo, M.
    Gupta, I.
    Knight, R. D.
    De Botton, S.
    Tallman, M. S.
    Kantarjian, H. M.
    LEUKEMIA RESEARCH, 2017, 55 : S24 - S25
  • [10] A PHASE I STUDY OF AG-221, A FIRST IN CLASS, POTENT INHIBITOR OF THE IDH2-MUTANT PROTEIN, IN PATIENTS WITH IDH2 MUTANT POSITIVE ADVANCED HEMATOLOGIC MALIGNANCIES
    Agresta, S.
    Stein, E. M.
    Tallman, M. S.
    Levine, R. L.
    Yua, H.
    Yen, K.
    Fan, B.
    Flinn, I. W.
    Fathi, A. T.
    Stone, R. M.
    DeAngelo, D. J.
    DeBotton, S.
    Pollyea, D. A.
    HAEMATOLOGICA, 2014, 99 : 789 - 789
123